Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162214 · ClinicalTrials.gov registry record · Phase 1
Study of Dasatinib in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00162214 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants.
The verdict
NCT00162214, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.
Interventions
- DRUG Dasatinib + Ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162214
The ClinicalTrials.gov registry entry for NCT00162214 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib + Ketoconazole is the first listed.
NCT00162214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162214 about?
NCT00162214 is a clinical study titled "Study of Dasatinib in Patients With Advanced Solid Tumors". The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.
What is the current status of trial NCT00162214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-08. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00162214?
The interventions under investigation include: Dasatinib + Ketoconazole (DRUG).
Who is sponsoring clinical trial NCT00162214?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.